Investor Notice: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Ardent Health, Inc. Shareholders

NEW YORK – January 14, 2026 — The national securities law firm Faruqi & Faruqi, LLP has announced that it is investigating potential legal claims on behalf of investors who suffered losses in Ardent Health, Inc. (“Ardent” or the “Company”) (NASDAQ: ARDT) securities. The firm is urging investors who purchased or acquired Ardent shares during the specified period to consider their rights and options.

Who Is Being Represented?

The notice applies to investors who purchased or acquired Ardent Health securities between July 18, 2024 and November 12, 2025. These investors are encouraged to contact Faruqi & Faruqi directly to discuss whether they may be eligible to participate in the current class action lawsuit and to seek appointment as a lead plaintiff in the federal securities class action that has already been filed against the Company. The deadline to seek lead plaintiff appointment is March 9, 2026.

Allegations Against Ardent Health

According to the complaint, Ardent Health and certain of its executives are accused of violating federal securities laws by:

• Making false or misleading statements about the Company’s financial condition; and
• Failing to disclose significant information related to how Ardent reported its accounts receivable and reserve levels for professional liability insurance.

During the so-called “Class Period,” defendants reported Ardent’s accounts receivable on a quarterly basis and stated that the Company maintained professional malpractice liability insurance in amounts sufficient to cover claims arising from its operations. However, the complaint alleges these statements were misleading or incomplete.

Details Behind the Stock Price Drop

On or around November 12, 2025, Ardent announced its third quarter 2025 financial results. The disclosure included:

• A $43 million reduction in revenue due to changes in how the Company accounted for certain items; and
• A $54 million increase in professional liability reserves.

This financial disclosure led to a significant decline in Ardent’s share price. On the following trading day, November 13, 2025, the stock fell by approximately 33.81% — closing at $9.30 per share — after the disclosure became public.

What Investors Should Know

Under federal securities law, any Ardent Health investor who bought or acquired securities during the class period and suffered financial losses may seek to participate in the lawsuit. Those interested in serving as the lead plaintiff — a representative investor who directs the class action litigation — must file a motion with the court before the March 9, 2026 deadline.

Being appointed as lead plaintiff gives a shareholder authority to guide the lawsuit and select legal counsel. However, investors who choose not to seek lead plaintiff status can still remain part of the class and share in any potential recovery without taking on leadership responsibilities.

How to Get More Information

Investors and individuals who believe they have information relevant to the case — including former employees, whistleblowers, or shareholders — are encouraged to contact Faruqi & Faruqi, LLP directly for further details. The law firm has offices across the United States, including New York, Pennsylvania, California, and Georgia, and has recovered hundreds of millions of dollars for investors in securities class actions since its founding in 1995.

For more information about the Ardent Health class action lawsuit and eligibility options, investors may visit the firm’s website or call the contact numbers provided in the official notice.